(Q33933252)

30 July 2017

title

Development and application of PROVAX adjuvant formulation for subunit cancer vaccines (English)

1 reference

30 July 2017

Hanna N

1

1 reference

30 July 2017

Hariharan K

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

Advanced Drug Delivery Reviews

30 July 2017

published in

1 reference

30 July 2017

volume

32

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

187-197

1 reference

Vaccine R&D success rates and development times

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Cancer vaccines: a road map for the next decade

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Cancer vaccines based on the identification of genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Immunobiology and immunotherapy of melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

1 reference

7 January 2021

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Emerging principles for the recognition of peptide antigens by MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Intracellular traffic and antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Association of class I major histocompatibility heavy and light chains induced by viral peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

1 reference

7 January 2021

T-cell immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Oncogenic proteins as tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

1 reference

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Cytokines, tumour-cell death and immunogenicity: a question of choice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

The new vaccines: building viruses that elicit antitumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Recombinant Listeria monocytogenes cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Introduction of soluble protein into the class I pathway of antigen processing and presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Can soluble antigens induce CD8+ cytotoxic T-cell responses? A paradox revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Human neoplasms elicit multiple specific immune responses in the autologous host

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

Biological properties of dendritic cells: implications to their use in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900010-6

7 January 2021

10.1016/S0169-409X(98)00010-6

Identifiers

DOI

1 reference

30 July 2017

1 reference